Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383059247> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4383059247 endingPage "5691" @default.
- W4383059247 startingPage "5684" @default.
- W4383059247 abstract "This study was performed to evaluate the efficacy of immediate cytoreductive nephrectomy (CRN) followed by programmed cell death factor-1 (PD-1) inhibitors vs. deferred CRN after the administration of 4 cycles of neoadjuvant therapy using nivolumab preceding the debulking and postoperative chemotherapy in metastatic renal cell carcinoma (mRCC).We recruited 84 patients with primary mRCC admitted to our Oncology Department from 2018 to 2020 and randomized them 1:1 to receive either CRN followed by nivolumab (control group) or 4 cycles of neoadjuvant therapy using nivolumab before CRN and postoperative chemotherapy (study group), with 42 patients in each group. The primary clinical endpoints were the clinical efficacy and safety of the PD-1 antibody. Clinical outcomes were assessed 3 months after treatment.Patients were followed-up for 10-52 months, with a median follow-up period of 40.50 months. The control group reported 2 cases of complete remission and 10 cases of partial remission, with an objective response rate (ORR) of 28.57% (12/42). The study group reported 4 cases of complete remission and 14 cases of partial remission with an ORR of 42.86% (18/42). No significant differences in the ORR were identified between the two groups (p > 0.05). Progression-free survival of the patients was significantly extended from 30 months (19-51) to 43 months (38-76) after administrating the PD-1 inhibitors before the debulking (HR = 0.501, 95% CI: 0.266 to 0.942). There were no significant differences in the median survival of patients between the two groups [44 months (38-79) vs. 44 months (32-81)] (HR = 0.814, 95% CI: 0.412 to 1.612). The two protocols had a similar safety profile.Nivolumab administration preceding delayed CRN provides significant progression-free survival benefits for patients with mRCC, but its impact on overall survival requires further investigations." @default.
- W4383059247 created "2023-07-05" @default.
- W4383059247 creator A5043033478 @default.
- W4383059247 creator A5048052584 @default.
- W4383059247 creator A5072435083 @default.
- W4383059247 creator A5086309026 @default.
- W4383059247 date "2023-06-01" @default.
- W4383059247 modified "2023-09-23" @default.
- W4383059247 title "Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma." @default.
- W4383059247 doi "https://doi.org/10.26355/eurrev_202306_32808" @default.
- W4383059247 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37401306" @default.
- W4383059247 hasPublicationYear "2023" @default.
- W4383059247 type Work @default.
- W4383059247 citedByCount "0" @default.
- W4383059247 crossrefType "journal-article" @default.
- W4383059247 hasAuthorship W4383059247A5043033478 @default.
- W4383059247 hasAuthorship W4383059247A5048052584 @default.
- W4383059247 hasAuthorship W4383059247A5072435083 @default.
- W4383059247 hasAuthorship W4383059247A5086309026 @default.
- W4383059247 hasConcept C121608353 @default.
- W4383059247 hasConcept C126322002 @default.
- W4383059247 hasConcept C126894567 @default.
- W4383059247 hasConcept C141071460 @default.
- W4383059247 hasConcept C143998085 @default.
- W4383059247 hasConcept C2776694085 @default.
- W4383059247 hasConcept C2777472916 @default.
- W4383059247 hasConcept C2777701055 @default.
- W4383059247 hasConcept C2780030458 @default.
- W4383059247 hasConcept C2780091579 @default.
- W4383059247 hasConcept C2780227381 @default.
- W4383059247 hasConcept C2780427987 @default.
- W4383059247 hasConcept C2781100745 @default.
- W4383059247 hasConcept C71924100 @default.
- W4383059247 hasConcept C90924648 @default.
- W4383059247 hasConceptScore W4383059247C121608353 @default.
- W4383059247 hasConceptScore W4383059247C126322002 @default.
- W4383059247 hasConceptScore W4383059247C126894567 @default.
- W4383059247 hasConceptScore W4383059247C141071460 @default.
- W4383059247 hasConceptScore W4383059247C143998085 @default.
- W4383059247 hasConceptScore W4383059247C2776694085 @default.
- W4383059247 hasConceptScore W4383059247C2777472916 @default.
- W4383059247 hasConceptScore W4383059247C2777701055 @default.
- W4383059247 hasConceptScore W4383059247C2780030458 @default.
- W4383059247 hasConceptScore W4383059247C2780091579 @default.
- W4383059247 hasConceptScore W4383059247C2780227381 @default.
- W4383059247 hasConceptScore W4383059247C2780427987 @default.
- W4383059247 hasConceptScore W4383059247C2781100745 @default.
- W4383059247 hasConceptScore W4383059247C71924100 @default.
- W4383059247 hasConceptScore W4383059247C90924648 @default.
- W4383059247 hasIssue "12" @default.
- W4383059247 hasLocation W43830592471 @default.
- W4383059247 hasOpenAccess W4383059247 @default.
- W4383059247 hasPrimaryLocation W43830592471 @default.
- W4383059247 hasRelatedWork W2075819945 @default.
- W4383059247 hasRelatedWork W2801460366 @default.
- W4383059247 hasRelatedWork W2977641481 @default.
- W4383059247 hasRelatedWork W2982664815 @default.
- W4383059247 hasRelatedWork W3025864022 @default.
- W4383059247 hasRelatedWork W3106649312 @default.
- W4383059247 hasRelatedWork W4212773757 @default.
- W4383059247 hasRelatedWork W4283784976 @default.
- W4383059247 hasRelatedWork W4285679063 @default.
- W4383059247 hasRelatedWork W4324129300 @default.
- W4383059247 hasVolume "27" @default.
- W4383059247 isParatext "false" @default.
- W4383059247 isRetracted "false" @default.
- W4383059247 workType "article" @default.